c-MET anticorps (Cytoplasmic Domain)

N° du produit ABIN614469

Détail du produit anti-c-MET anticorps

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Épitope: Cytoplasmic Domain

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp c-MET est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Specificité: Recognizes c-Met (Cytoplasmic Domain).

Réactivité croisée (Details): Species reactivity (tested):Human.

Purification: Purified

Immunogène: Synthetic peptide derived from cytoplasmic domain of Human c-Met protein

Clone: IST-1

Isotype: IgG2a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: PBS, 7.4 containing 1 % BSA and 0.09 % Sodium Azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur c-MET

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Autre désignation: HGF Receptor (MET Produits)

Synonymes: anticorps AUTS9, anticorps HGFR, anticorps RCCP2, anticorps c-Met, anticorps AI838057, anticorps HGF, anticorps Par4, anticorps Hgfr, anticorps c-met, anticorps MET, anticorps C-MET, anticorps met, anticorps met-A, anticorps MET proto-oncogene, receptor tyrosine kinase, anticorps met proto-oncogene, anticorps MET proto-oncogene, receptor tyrosine kinase L homeolog, anticorps MET, anticorps Met, anticorps met.L

Sujet: The c-Met protein is a receptor tyrosine kinase encoded by the c-Met proto-oncogene. c-Met, also known as HGF receptor or SF receptor, is activated by hepatocyte growth factor (HGF) or scatter factor (SF), and is composed of alpha and beta subunits linked by disulfide bonds. Dysregulated c-Met expression has been detected at both protein and mRNA levels in a variety of human carcinomas and sarcomas. Up to a 2.5-fold increase in mRNA expression has been reported in colorectal tumor tissues, and upregulation of the c-Met protein in association with increasingly malignant behavior has been described in prostate cancer, cutaneous malignant melanoma, and breast cancer. Recent studies using monoclonal Ms anti-c-Met (clone: 3D4) for immunohistochemistry in lymph node-negative breast carcinoma tissues demonstrated that high levels of c-Met expression are associated with poor patient clinical outcome, as assessed over 20-40 years of follow-up. Further, antibodies against the intracellular but not the extracellular domain of c-Met were prognostic, suggesting that overexpression of the cytoplasmic tail of c-Met may play an important role in breast cancer progression.Synonyms: HGF/SF receptor, Hepatocyte growth factor receptor, MET, Met proto-oncogene tyrosine kinase, Scatter factor receptor, c-Met

ID gène: 4233

NCBI Accession: NP_000236

UniProt: P08581

Pathways: Signalisation RTK, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor